Patent intelligence · US
US 10869846
N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
Patent details — US 10869846
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 22, 2020
- Expiration
- Dec 17, 2040
- Applicant
- SENTIENT LIFESCIENCES, INC.
- Claims
- 15
- CPC classes
- A61K, A61K31/16, A61K31/167, A61K31/375
Quick answer
US 10869846 (N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress) is held by SENTIENT LIFESCIENCES, INC.. Status: granted. Granted Dec 22, 2020. Expires Dec 17, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SENTIENT LIFESCIENCES, INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/16, A61K31/167, A61K31/375, A61K9/0014, A61K9/0019
More from SENTIENT LIFESCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419895
Methods for treating subjects with Prader-Willi syndrome
granted -
US 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatological health
granted -
US 12343348
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12343381
Dosage regimen for pegylated interferon
granted -
US 12178823
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 12005081
Chimeric receptors and methods of use thereof
granted -
US 11884656
Pyrrole derivatives as PLK1 inhibitors
granted
Frequently asked questions
What is US patent 10869846?
US 10869846 (N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress) is held by SENTIENT LIFESCIENCES, INC.. Status: granted. Granted Dec 22, 2020. Expires Dec 17, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10869846?
SENTIENT LIFESCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.
When does US 10869846 expire?
Our index shows an expiration date of Dec 17, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.